Arch Capital Group heads into its July 28 Q2 earnings report with the stock up 6% on the week and analysts nudging targets higher — a setup that puts the upcoming print squarely in focus.
The stock closed at $102.85 on Tuesday, its best one-week performance in months. The broader insurance group moved in the same direction: close peers CB and HIG each gained around 4.6% on the week, while AXS added 5.2%. ACGL outpaced most of the group, though nearest comparator RNR barely moved, up just 0.2%. The divergence is worth noting — Arch is catching a bid that its reinsurance sibling is not.
Analyst activity this week sharpens the bull-versus-bear tension. The clearest signal came today from UBS, where Brian Meredith — maintaining a Buy — raised his target from $114 to $120, the highest target in the recent-changes list. That followed Morgan Stanley lifting its Overweight target from $105 to $110 earlier in the week. Set against that, Keefe Bruyette & Woods moved in the opposite direction today, trimming its Market Perform target from $102 to $99 — the only analyst now with a target below the current price. The consensus mean sits at $109.39, implying roughly 6% upside from here, which is tighter than it was a month ago as the stock has run. Bulls point to the Reinsurance segment's structural growth — gross written premiums in that unit have grown from $1.9 billion in 2018 to over $11 billion in 2024 — and rising net investment income as a second engine. Bears flag a 13.5% year-over-year decline in property premiums in Q2 2025 and project underwriting income could fall nearly 25% by 2027 as pricing competition bites and the combined ratio drifts. Valuation tells the same ambiguous story: the P/E multiple has contracted about 0.6 turns over thirty days, while EPS surprise ranks in the 80th percentile — a company that consistently beats, but one the market is paying less for.
Positioning tells a relaxed story. Short interest is modest at 2.4% of free float — essentially unchanged on the week after a brief mid-June dip — and the borrow market is about as uncrowded as it gets. Availability is at 2,762%, meaning roughly 168 million shares are available to lend against fewer than 9 million currently borrowed. Cost to borrow has drifted below 0.51%, down about 5% over the past month, with no sign of pressure building. The put/call ratio at 1.47 looks tame relative to its 20-day average of 1.62 — options positioning has actually become less defensive as the stock rallied, after a sharp spike to 3.27 on June 22 that has since fully unwound. The ORTEX short score of 35.5 ranks in the 44th percentile, squarely in the middle of the universe. Nothing in the lending or derivatives market suggests bears are pressing their case ahead of earnings.
The last three earnings prints produced an average next-day move of roughly -2% to +1%, with the Q1 2026 result on May 5 delivering a modest +1.1% gain while the Q4 2025 print on April 28 dropped 3.8%. The pattern is consistent with what you'd expect from a specialty insurer in a transitioning pricing cycle — reactions are moderate but have skewed negative on beats that disappointed on underlying metrics. With the stock already up 13% over the past month, the bar for a positive reaction on July 28 is somewhat higher than it was after the April print.
The key tension to watch into July 28 is whether Arch can show stabilisation in property premium trends and any narrowing of the combined ratio trajectory — if those two lines hold, the UBS $120 target becomes the anchor; if they don't, the KBW bear case at $99 looks less lonely.
See the live data behind this article on ORTEX.
Open ACGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
